Blatt J - Search Results

1

Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation.

Aw WY, Cho C, Wang H, Cooper AH, Doherty EL, Rocco D, Huang SA, Kubik S, Whitworth CP, Armstrong R, Hickey AJ, Griffith B, Kutys ML, Blatt J, Polacheck WJ. Aw WY, et al. Among authors: blatt j. Sci Adv. 2023 Feb 15;9(7):eade8939. doi: 10.1126/sciadv.ade8939. Epub 2023 Feb 15. Sci Adv. 2023. PMID: 36791204 Free PMC article.

2

Notch signaling pathway is a potential therapeutic target for extracranial vascular malformations.

Davis RB, Pahl K, Datto NC, Smith SV, Shawber C, Caron KM, Blatt J. Davis RB, et al. Among authors: blatt j. Sci Rep. 2018 Dec 20;8(1):17987. doi: 10.1038/s41598-018-36628-1. Sci Rep. 2018. PMID: 30573741 Free PMC article.

3

A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations.

Blatt J, McLean TW, Castellino SM, Burkhart CN. Blatt J, et al. Pharmacol Ther. 2013 Sep;139(3):327-33. doi: 10.1016/j.pharmthera.2013.05.001. Epub 2013 May 8. Pharmacol Ther. 2013. PMID: 23665062 Review.

4

Genetics of hemangiomas, vascular malformations, and primary lymphedema.

Blatt J, Powell CM, Burkhart CN, Stavas J, Aylsworth AS. Blatt J, et al. J Pediatr Hematol Oncol. 2014 Nov;36(8):587-93. doi: 10.1097/MPH.0000000000000260. J Pediatr Hematol Oncol. 2014. PMID: 25222064 Review.

5

Author Correction: Notch signaling pathway is a potential therapeutic target for extracranial vascular malformations.

Davis RB, Pahl K, Datto NC, Smith SV, Shawber C, Caron KM, Blatt J. Davis RB, et al. Among authors: blatt j. Sci Rep. 2020 Jan 30;10(1):1847. doi: 10.1038/s41598-020-58751-8. Sci Rep. 2020. PMID: 31996757 Free PMC article.

6

Treatment of childhood kaposiform hemangioendothelioma with sirolimus.

Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Blatt J, et al. Pediatr Blood Cancer. 2010 Dec 15;55(7):1396-8. doi: 10.1002/pbc.22766. Pediatr Blood Cancer. 2010. PMID: 20730884

7

Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.

Coulter DW, Walko C, Patel J, Moats-Staats BM, McFadden A, Smith SV, Khan WA, Bridges AS, Deal AM, Oesterheld J, Davis IJ, Blatt J. Coulter DW, et al. Among authors: blatt j. Anticancer Drugs. 2013 Apr;24(4):415-21. doi: 10.1097/CAD.0b013e32835dc7c5. Anticancer Drugs. 2013. PMID: 23328074 Free PMC article. Clinical Trial.

8

How we approach complex vascular anomalies and overgrowth syndromes.

Watson KD, Kim KR, Blatt J. Watson KD, et al. Among authors: blatt j. Pediatr Blood Cancer. 2022 Aug;69 Suppl 3:e29273. doi: 10.1002/pbc.29273. Pediatr Blood Cancer. 2022. PMID: 36070209 Review.

9

Infectious complications of vascular anomalies treated with sirolimus: A systematic review.

Kalbfell R, Cohen-Cutler S, Grisham E, Bereitschaft C, Borst AJ, Green AM, Willis DN, Yaeger L, Blatt J, Sisk BA. Kalbfell R, et al. Among authors: blatt j. Pediatr Blood Cancer. 2024 Jan;71(1):e30758. doi: 10.1002/pbc.30758. Epub 2023 Nov 6. Pediatr Blood Cancer. 2024. PMID: 37933207 Review.

10

Wilms tumor associated with hirschsprung disease.

Blatt J, Nakayama D. Blatt J, et al. J Pediatr Hematol Oncol. 2007 Dec;29(12):858-9. doi: 10.1097/MPH.0b013e31815a0589. J Pediatr Hematol Oncol. 2007. PMID: 18090939

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters